There are 2137 resources available
269P - Real world treatment patterns and clinical outcomes associated with palbociclib combination therapy in five European countries: Results from the IRIS study
Presenter: Gavin Taylor-Stokes
Session: E-Poster Display
Resources:
Abstract
270P - Apatinib added to taxanes and platinum neoadjuvant chemotherapy for patients with triple-negative and HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial
Presenter: Yunjiang Liu
Session: E-Poster Display
Resources:
Abstract
271P - MAPK pathway inhibition as a rational therapeutic strategy for MiR-138-5p/PAQR3 dysregulation-mediated epirubicin resistance in triple-negative breast cancer
Presenter: Jianbo Huang
Session: E-Poster Display
Resources:
Abstract
272TiP - Dual-layer spectral detector CT: Clinical performance in patients with locally advanced breast cancer treated neoadjuvant with aromatase inhibitors
Presenter: Joana Reis
Session: E-Poster Display
Resources:
Abstract
284P - Interest of a multidisciplinary approach in the initiation of oral therapies in metastatic breast cancer (MBC): Experience of a French comprehensive cancer center
Presenter: Charlotte Dupont
Session: E-Poster Display
Resources:
Abstract
285P - Radiotherapy benefit in oligoprogressive breast cancer: A retrospective analysis
Presenter: Fabio Marazzi
Session: E-Poster Display
Resources:
Abstract
286P - Artificial intelligence analysis of advanced breast cancer patients from a phase I trial of trastuzumab deruxtecan (T-DxD): HER2 and histopathology features as predictors of clinical benefit
Presenter: Shanu Modi
Session: E-Poster Display
Resources:
Abstract
287P - Efficacy, safety and pharmacokinetics of a proposed trastuzumab biosimilar HLX02 compared with trastuzumab in metastatic breast cancer: A global phase III study
Presenter: Qingyuan Zhang
Session: E-Poster Display
Resources:
Abstract
288P - Final results from PERUSE, a global study of pertuzumab (P), trastuzumab (H) and investigator’s chosen taxane as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (LR/mBC)
Presenter: David Miles
Session: E-Poster Display
Resources:
Abstract
289P - Risk factors for interstitial lung disease in patients treated with trastuzumab deruxtecan from two interventional studies
Presenter: Charles Powell
Session: E-Poster Display
Resources:
Abstract